The brain tumor immune microenvironment (TIME) continuously evolves during glioma progression, but only a limited view of a highly complex glioma associated immune contexture across isocitrate dehydrogenase mutation (IDH) classified gliomas is known. Herein, we present an unprecedentedly comprehensive view of myeloid and lymphoid cell type diversity with our m-RNA sequencing interrogation. Overall design: The glioma associated CD45+ (n=15) and CD45hi (n=3) and CD45lo (n=3) leukocyte fractions were subjected to Fluorescence-activated cell sorting (FACS) from cryopreserved single cells. The leukocyte enriched single cell suspensions were obtained from freshly resected tumors of IDH-mutant primary (IMP; n=3), IDH-mutant recurrent (IMR; n=4), IDH-wild type primary (IWP; n=4), or IDH-wild type recurrent (IWR; n=4) glioma patients and quasi-normal non-glioma brain (NGB; n=1) from a dysembryoplastic neuroepithelial tumor. *** Raw data are not provided for this study. Raw data are protected by MD Anderson internal review board (IRB)-approved protocol numbers LAB03-0687, LAB04-0001 and 2012-0441 and Baylor College of Medicine IRB-approved protocol number H-13798. ***